These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
43. [Gold therapy in chronic polyarthritis. Differentiation of allergic and toxic side effects]. Bene E; Megyeri A; Györi J Z Rheumatol; 1980; 39(3-4):109-16. PubMed ID: 6448525 [TBL] [Abstract][Full Text] [Related]
44. Penicillamine in the treatment of rheumatoid arthritis. Camp AV J Rheumatol Suppl; 1981; 7():103-6. PubMed ID: 6939871 [TBL] [Abstract][Full Text] [Related]
45. Disease-modifying agents in rheumatoid arthritis. Lipsky PE Ryumachi; 1987 Dec; 27(6):409-12. PubMed ID: 2455354 [No Abstract] [Full Text] [Related]
47. Drugs in the management of rheumatoid arthritis. Bresnihan B Ir Med J; 1982 Jan; 75(1):7-9. PubMed ID: 6806208 [No Abstract] [Full Text] [Related]
48. Remission-inducing drugs in rheumatoid arthritis. Anastassiades TP Can Med Assoc J; 1980 Feb; 122(4):405-15. PubMed ID: 6768438 [TBL] [Abstract][Full Text] [Related]
49. [Current status of D-penicillamine therapy in chronic polyarthritis]. Franke M; Menning H; Ströbel G Z Rheumatol; 1981; 40(2):54-61. PubMed ID: 7282106 [TBL] [Abstract][Full Text] [Related]
50. Rheumatoid arthritis V: therapy with remission-inducing agents. Gaines LM Md State Med J; 1982 Sep; 31(9):49-50. PubMed ID: 6815385 [No Abstract] [Full Text] [Related]
51. [Long-term drug therapy in inflammatory rheumatic diseases using chronic polyarthritis as an example. 2. Basic principles of long-term drug therapy: choice of optimal therapeutic agents]. Menninger H; Burkhardt H Fortschr Med; 1983 Apr; 101(14):639-45. PubMed ID: 6406333 [TBL] [Abstract][Full Text] [Related]
52. [5-year treatment of rheumatoid polyarthritis with D-penicillamine]. Duquesnoy B; Cocheteux P; Siame JL; Delcambre B Sem Hop; 1983 May; 59(21):1641-4. PubMed ID: 6310780 [TBL] [Abstract][Full Text] [Related]
53. [Antibodies to D-penicillamine in patients with chronic polyarthritis--diagnostic aid in undesired and insufficient drug effects?]. Storch W; Keitel W Z Rheumatol; 1988; 47 Suppl 1():44-7. PubMed ID: 3213272 [TBL] [Abstract][Full Text] [Related]
54. Relationship of gold and penicillamine therapy to diffuse interstitial lung disease. Scott DL; Bradby GV; Aitman TJ; Zaphiropoulos GC; Hawkins CF Ann Rheum Dis; 1981 Apr; 40(2):136-41. PubMed ID: 6784683 [TBL] [Abstract][Full Text] [Related]
55. Sulphasalazine in rheumatoid arthritis: combination therapy with D-penicillamine or sodium aurothiomalate. Farr M; Kitas G; Bacon PA Clin Rheumatol; 1988 Jun; 7(2):242-8. PubMed ID: 2901303 [TBL] [Abstract][Full Text] [Related]
56. Complement C4 null alleles as a marker of gold or D-penicillamine toxicity in the treatment of rheumatoid arthritis. Clarkson RW; Sanders PA; Grennan DM Br J Rheumatol; 1992 Jan; 31(1):53-4. PubMed ID: 1730108 [TBL] [Abstract][Full Text] [Related]
57. Chrysotherapy and thrombocytopenia. Madhok R; Pullar T; Capell HA; Dawood F; Sturrock RD; Dick HM Ann Rheum Dis; 1985 Sep; 44(9):589-91. PubMed ID: 3929704 [TBL] [Abstract][Full Text] [Related]
58. Sequential gold and penicillamine therapy in rheumatoid arthritis. Halla JT; Cassady J; Hardin JG Am J Med; 1982 Mar; 72(3):423-6. PubMed ID: 6174045 [TBL] [Abstract][Full Text] [Related]
59. [Penicillamine D in primary chronic polyarthritis. A long-term study]. Hadidi T Med Welt; 1976 Feb; 27(7):333-6. PubMed ID: 1256297 [No Abstract] [Full Text] [Related]
60. HLA antigens and drug toxicity in rheumatoid arthritis. Ford PM J Rheumatol; 1984 Jun; 11(3):259-61. PubMed ID: 6610749 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]